Skip to main content
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years https://t.co/9YNEGXKoAD #RA #filgotinib low vte & low zoster rates
Peter Nash
07-11-2020
×